Janssen Search
Search results
Update on Janssen’s BACE Inhibitor Program
Update on Janssen’s BACE Inhibitor Program May 18, 2018 Titusville, NJ, May 17, 2018- At Janssen, the safety and well-being of people who participate in our clinical trials are of utmost importance to us. For the past several years, we have been studying ...
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Jun 28, 2024 Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADL ...
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress
Oct 09, 2023 United States 30 presentations showcase breadth of data from Janssen’s Immunodermatology pipeline across five commercialized and investigational therapies SPRING HOUSE, PENNSYLVANIA, October 9, 2023 – Janssen Pharmaceuticals, Inc., a ...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Jul 22, 2024 Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of ...
Eric George, Ph.D.
As the Presbyopia/Cataracts Venture Leader of the Disease Interception Accelerator (DIA), Eric George leads the team’s efforts in exploring solutions aimed at stopping the progression of presbyopia and cataracts. Prior to joining the DIA, Eric worked for ...
Innovating HIV Treatment and Prevention
Innovating HIV Treatment and Prevention Expanding Access to HIV Treatment is a Top Global Public Health Priority Janssen is exploring innovative applications of our HIV medicines to help address treatment and prevention outcomes in hard-to-reach areas by ...
Living the Principles of Green Chemistry
Living the Principles of Green Chemistry Our series on green chemistry continues with an exploration of how we at Janssen approach and activate these vital principles. Click here for a primer on green chemistry, and watch this space for additional ...
New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement
Oct 23, 2023 United States Data from the QUASAR induction study of a dults with moderate to severely active ulcerative colitis show clinically meaningful results at Weeks 12 or 24 Additional data show symptomatic response as early as one week after the ...
Transparency and Collaboration
Transparency and Collaboration At Janssen, we believe transparency helps to advance science and medicine; it’s in the best interests of both the people who use our pharmaceutical products and providers who prescribe them. The people and healthcare ...
Grants & Giving
“We are responsible to the communities in which we live and work.” Our Responsibilities Guide Our Charitable Giving Article Type: Grants Giving Our responsibilities, as set forth in Our Credo, guide Janssen's charitable giving. In administering our ...